Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathryn Ball

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Biopharmaceutics & Drug Disposition|January 10, 2012
Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?François Bouzom, Kathryn Ball, Nathalie Perdaems, et al.
Mabs|February 23, 2023
Strategies for clinical dose optimization of T cell-engaging therapies in oncologyKathryn Ball, Simon J Dovedi, Pavan Vajjah, et al.
Journal of Surgical Case Reports|December 15, 2022
A case report on a rare presentation of adrenal myelolipoma with low-impact traumatic haemorrhage and the challenges of conservative managementBronte Paice, Taiwo Oyebola, Kathryn Ball, et al.
Biopharmaceutics & Drug Disposition|July 22, 2014
Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and humanKathryn Ball, François Bouzom, Jean-Michel Scherrmann, et al.
Journal of Pharmaceutical Sciences|August 7, 2012
Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodoneKathryn Ball, François Bouzom, Jean-Michel Scherrmann, et al.
Molecular Pharmaceutics|January 23, 2014
A physiologically based modeling strategy during preclinical CNS drug developmentKathryn Ball, François Bouzom, Jean-Michel Scherrmann, et al.
The AAPS Journal|June 21, 2013
Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approachKathryn Ball, François Bouzom, Jean-Michel Scherrmann, et al.
EMBO Reports|August 5, 2003
Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domainAshley Craig, Mary Scott, Lindsay Burch, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 30, 2017
Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modellingKathryn Ball, Tanguy Jamier, Yannick Parmentier, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 17, 2022
Development of and insights from systems pharmacology models of antibody-drug conjugatesInez Lam, Venkatesh Pilla Reddy, Kathryn Ball, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Biopharmaceutics & Drug Disposition|January 10, 2012
Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?François Bouzom, Kathryn Ball, Nathalie Perdaems, et al.
Mabs|February 23, 2023
Strategies for clinical dose optimization of T cell-engaging therapies in oncologyKathryn Ball, Simon J Dovedi, Pavan Vajjah, et al.
Journal of Surgical Case Reports|December 15, 2022
A case report on a rare presentation of adrenal myelolipoma with low-impact traumatic haemorrhage and the challenges of conservative managementBronte Paice, Taiwo Oyebola, Kathryn Ball, et al.
Biopharmaceutics & Drug Disposition|July 22, 2014
Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and humanKathryn Ball, François Bouzom, Jean-Michel Scherrmann, et al.
Journal of Pharmaceutical Sciences|August 7, 2012
Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodoneKathryn Ball, François Bouzom, Jean-Michel Scherrmann, et al.
Molecular Pharmaceutics|January 23, 2014
A physiologically based modeling strategy during preclinical CNS drug developmentKathryn Ball, François Bouzom, Jean-Michel Scherrmann, et al.
The AAPS Journal|June 21, 2013
Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approachKathryn Ball, François Bouzom, Jean-Michel Scherrmann, et al.
EMBO Reports|August 5, 2003
Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domainAshley Craig, Mary Scott, Lindsay Burch, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 30, 2017
Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modellingKathryn Ball, Tanguy Jamier, Yannick Parmentier, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 17, 2022
Development of and insights from systems pharmacology models of antibody-drug conjugatesInez Lam, Venkatesh Pilla Reddy, Kathryn Ball, et al.
Pageof 4